Ovid Therapeutics (OVID) Competitors

Inhibrx (NASDAQ:INBX) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation, profitability and community ranking.

Do insiders & institutionals have more ownership in INBX or OVID?

82.5% of Inhibrx shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 22.2% of Inhibrx shares are held by insiders. Comparatively, 13.3% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Do analysts prefer INBX or OVID?

Ovid Therapeutics has a consensus target price of $4.03, indicating a potential upside of 553.17%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Inhibrx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ovid Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor INBX or OVID?

Ovid Therapeutics received 324 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 70.86% of users gave Ovid Therapeutics an outperform vote while only 58.49% of users gave Inhibrx an outperform vote.

Company	Underperform	Outperform
Inhibrx	Outperform Votes 31 58.49%	Underperform Votes 22 41.51%
Ovid Therapeutics	Outperform Votes 355 70.86%	Underperform Votes 146 29.14%

Does the media prefer INBX or OVID?

In the previous week, Inhibrx had 3 more articles in the media than Ovid Therapeutics. MarketBeat recorded 3 mentions for Inhibrx and 0 mentions for Ovid Therapeutics. Inhibrx's average media sentiment score of 1.43 beat Ovid Therapeutics' score of -0.59 indicating that Inhibrx is being referred to more favorably in the media.

Company	Overall Sentiment
Inhibrx	Positive
Ovid Therapeutics	Negative

Which has stronger valuation & earnings, INBX or OVID?

Ovid Therapeutics has lower revenue, but higher earnings than Inhibrx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx	$1.63M	111.58	-$154.96M	N/A	N/A
Ovid Therapeutics	$390K	112.43	-$52.34M	-$0.47	-1.31

Is INBX or OVID more profitable?

Inhibrx has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -5,142.56%. Ovid Therapeutics' return on equity of -39.24% beat Inhibrx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx	N/A	-113.74%	-80.56%
Ovid Therapeutics	-5,142.56%	-39.24%	-26.19%

Summary

Ovid Therapeutics beats Inhibrx on 10 of the 16 factors compared between the two stocks.